Zeidner, J. F., Lin, T. L., Welkie, R. L., Curran, E., Koenig, K., Stock, W., Madanat, Y. F., Swords, R., Baer, M. R., Blum, W., Stein, E. M., Olin, R. L., Schiller, G., Nichols, A., Odenike, O., Traer, E., Lachowiez, C., Duong, V. H., Hochman, M. J., Cai, S. F., Smith, C., Stefanos, M., Martycz, M., Huang, Y., Rosenberg, L., Marcus, S., Chen, T. L., Yocum, A. O., Druker, B. J., Levine, R. L., Borate, U., Byrd, J. C., Mims, A. S. (2025). Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed
                    <i>NPM1</i>
                    -Mutated or
                    <i>KMT2A</i>
                    -Rearranged AML. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00914